NCT07142135

Brief Summary

Klinefelter syndrome (KS) is the most frequent sex chromosome disorder affecting approximately 1:660 newborn boys. The prevalence of KS rises to 3-4% among infertile males and 10-15% in patients with non-obstructive azoospermia. KS is highly underdiagnosed, and diagnosis is often delayed. Phenotypic variability, and especially a presentation with mild clinical features, often leads to diagnostic delay or non-diagnosis. It has been estimated that 50-75% of males with KS never obtain a diagnosis (Berglund et al., 2019; Bojesen et al., 2003). Despite increasing interest in studying KS during recent years there remain significant gaps in our overall understanding of KS, including when and how to start testosterone replacement therapy (TRT), how to prevent co-morbidities, mechanisms of complications, success of fertility preservation and assessment of quality of life in affected individuals. This translates into differences in standards of care for these patients, with substantial variability in clinical practice. International guidelines regarding the care of patients with KS were published by the European Academy of Andrology/European Society of Endocrinology in 2021 (Zitzmann et al., 2021) to improve the clinical care of these patients. These guidelines, however, are limited by a general lack of scientific evidence due to the low number of studies in the field. This increases the need to systematically collect more information to develop individualized and optimized care for future patients. The investigators therefore aim to systematically describe the phenotype of Klinefelter syndrome throughout life by collecting clinical, biochemical, genetic, and radiological data on reproductive development, fertility, anthropometry, bone age, body composition, bone mineralization, co-morbidities, biomarkers of general health as well as psychopathology and mental health. Hypotheses:

  1. 1.Patients with KS may differ from controls in their biological health profile (hormonal, thyroid, metabolic, inflammatory, genetic, and epigenetic) which may affect their lifestyle and alter disease risk. Detailed knowledge about such alterations and at what age they appear may facilitate more individualized and optimized treatment regimens with the goal to prevent co-morbidities.
  2. 2.Hypertension, bradycardia and long QTc may be more frequently present in adults with KS. The investigators hypothesise that both blood pressure and electro cardiograph (ECG) are normal in childhood and adolescence. Knowledge about the mechanisms behind these phenomena and when they appear will help us in understanding the biological mechanism and in optimizing preventive interventions.
  3. 3.Men with KS are taller than their genetic potential. This may at least in part be attributed to an increased growth velocity through childhood before puberty.
  4. 4.Genetic and epigenetic alterations may explain the phenotypic variability and the associated co-morbidities may be caused by such alterations.
  5. 5.Virilization (penis length and width, pubic hair development, voice frequency) is impaired in adolescents and adults with KS.
  6. 6.Patients with KS face a greatly increased risk of being affected by psychopathology such as attention deficit and hyperactivity disorder (ADHD) and depression. In addition to the clinically observable lack of energy (fatigue) and social withdrawal, this may affect quality of life, and impact long-term mental health. Learning more about the factors supporting mental health in boys and men with KS will significantly advance our chances of alleviating these common complaints and preventing long-term complications.
  7. 7.Patients with KS may have distinct facial characteristics. Knowledge about such characteristics may increase the likelihood of identifying patients with KS and thereby improve the diagnostic delay.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
106mo left

Started Apr 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress11%
Apr 2025Jan 2035

Study Start

First participant enrolled

April 1, 2025

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

August 18, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 26, 2025

Completed
9.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2035

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2035

Last Updated

September 10, 2025

Status Verified

September 1, 2025

Enrollment Period

9.8 years

First QC Date

August 18, 2025

Last Update Submit

September 3, 2025

Conditions

Keywords

Klinefelter syndromesex chromosome

Outcome Measures

Primary Outcomes (1)

  • DXA scan

    Whole body DXA scan

    DXA will be performed once

Study Arms (1)

Klinefelter syndrome

Other: There is no intervention, only clinical description

Interventions

There is no intervention, only clinical description

Klinefelter syndrome

Eligibility Criteria

Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Approximately 300 patients with these diagnoses are currently followed at The Department of Growth and Reproduction and are eligible for inclusion in this study.

You may qualify if:

  • Patients with karyotype 47,XXY or variants as mentioned above who are followed at the Department of Growth and Reproduction, Rigshospitalet, Denmark, can be included in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Copenhagen University Hospital, Rigshospitalet, Department of Growth and Reproduction

Copenhagen, 2100, Denmark

Location

MeSH Terms

Conditions

Klinefelter Syndrome

Condition Hierarchy (Ancestors)

Sex Chromosome Disorders of Sex DevelopmentDisorders of Sex DevelopmentUrogenital AbnormalitiesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesSex Chromosome DisordersChromosome DisordersCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGenetic Diseases, InbornGonadal DisordersEndocrine System DiseasesHypogonadism

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 18, 2025

First Posted

August 26, 2025

Study Start

April 1, 2025

Primary Completion (Estimated)

January 1, 2035

Study Completion (Estimated)

January 1, 2035

Last Updated

September 10, 2025

Record last verified: 2025-09

Locations